BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will participate in
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcast will be available for 90 days.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.
Subscribe to our Free Newsletters!